Skip to main content
Indiana University School of Medicine distinguished professor Debomoy Lahiri, PhD, has been named a 2022 fellow of the National Academy of Inventors – the highest professional distinction awarded to academic inventors.

Neuroscience researcher Debomoy Lahiri, PhD, elected to National Academy of Inventors

Debomoy Lahiri, PhD

Debomoy Lahiri, PhD

INDIANAPOLIS–Indiana University School of Medicine distinguished professor Debomoy Lahiri, PhD, has been named a 2022 fellow of the National Academy of Inventors–the highest professional distinction awarded to academic inventors. The fellows will be honored during the academy's annual meeting in June.

The National Academy of Inventors' Fellows Program highlights academic inventors who have demonstrated a spirit of innovation in creating or facilitating outstanding inventions that have made a tangible impact on the quality of life, economic development and the welfare of society.

Lahiri's research focuses on the neurobiology and genetics of aging and Alzheimer's disease. His work has led to several United States and international patents related to neurodegenerative diseases and neurodevelopmental disorders.

"My primary research interest is understanding how degeneration of brain cells under laboratory conditions can be more closely made to resemble the 'natural' neurodegeneration of Alzheimer's disease. This system can be used to test drugs to prevent or even reverse Alzheimer's-related degeneration," Lahiri said. "I am honored to be named a 2022 fellow along with so many other scientific innovators across the country. It is a team effort. I truly feel lucky to get this recognition and enormously benefitted from the help and support of my colleagues at IU School Medicine, other collaborators and the National Institutes of Health."

Some of Lahiri's most notable work includes:

  • The development of Posiphen, also known as Buntanetap, is an experimental drug currently in late-stage clinical trials for Alzheimer's disease and related disorders. Research by Lahiri found that Posiphen lowered amyloid-beta peptide levels in cell culture and mice. This work is significant as the presence of amyloid-beta peptide-loaded neuritic plaques is one of the hallmarks of Alzheimer’s disease.
  • The invention of cellular and biochemical approaches to prevent the accumulation of potentially toxic amyloid beta peptide in the central nervous system. These methods involve administering a chemical compound that can penetrate the blood-brain barrier to patients at risk of developing dementia. Both Alzheimer's and Down syndrome patients would benefit from the model, as Down syndrome has been linked to increased brain amyloid levels and early-onset Alzheimer's disease. Lahiri invented methods for the stimulation of synthesis of synaptophysin, an integral membrane protein localized to neurotransmitter-bearing vesicles.
  • Demonstrating the use of memantine, a drug used to treat Alzheimer’s disease symptoms, to modify the deposition of proteins associated with neurodegeneration. Specifically, the invention relates to the ability of memantine to intervene in the processing of amyloid-beta precursor protein and decrease the levels of fibrillogenic amyloid beta peptides. This invention was licensed to AbbVie, a subsidiary of Forest Laboratories in New York City.
  • The discovery of a relationship between Alzheimer's disease-associated proteins, autism spectrum disorder, and fragile X syndrome. Lahiri co-invented a method to monitor autism spectrum disorder and fragile X syndrome patients by measuring blood plasma levels of a molecule involved in changes to learning and memory and using these levels to adjust the dose of a therapeutic compound called acamprosate. The co-invention of methods to treat neurodegenerative diseases by targeting inflammatory pathways. This invention provides pharmaceutical compositions comprising rationally designed peptides that interfere with the NF-κB signaling pathway, which has been a catalyst for intense drug discovery and development.
  • The invention of a novel genomic DNA extraction method from human subjects, which led to several genomics discoveries. This method is used in laboratories worldwide for human genome mapping and genotyping, and the research has been cited by peer scientists over 2,700 times – a record number of citations for a research publication from a single IU School of Medicine lab. From DNA to RNA, Lahiri lab’s recent discovery of a more novel target for neurodegenerative disease therapies involve the unique roles of specific microRNA species in Alzheimer's disease.
  • Proposing the “Latent Early-life Associated Regulation” (LEARn) pathway that unites genes and the environment. Over time, environmentally induced epigenomic changes can result in an increased risk of dementia, but individually these changes are essentially latent. The biochemical basis of LEARn leads to a novel remedial possibility that a high-risk individual’s impending dementia could be averted through environmental changes, including not only therapeutic intervention but also healthy lifestyle choices and other environmental adjustments.

"Such important academic inventions await additional work to translate their findings to benefit people," said Lahiri, who also serves as editor-in-chief of the journal Current Alzheimer Research. "The ultimate goals of these efforts are to develop molecular methods for diagnoses and to devise rational neuroprotective strategies for the prevention and treatment of age-related disorders."

In addition to his research, Lahiri actively promotes public awareness of neuroscience education and has been elected as a fellow of the American Association of the Advancement of Sciences.

Lahiri is one of 169 academic inventors named a National Academy of Inventors fellow this year. The 2022 fellows are from 110 research universities and worldwide governmental and nonprofit research institutes. They collectively hold over 4,800 issued U.S. patents.

"This year's class of NAI fellows represents a truly outstanding caliber of innovators. Each of these individuals has significantly impacted through their work and is highly regarded in their respective fields," said Paul R. Sanberg, PhD, DSc, president of the National Academy of Inventors. "The breadth and scope of their inventions are truly staggering. I am excited to see their creativity continue to define a new era of science and technology in the global innovation ecosystem."

To date, fellows of the academy hold more than 58,000 issued U.S. patents, which have developed over 13,000 licensed technologies and companies, and created more than one million jobs. In addition, over $3 trillion in revenue has been generated based on fellows' discoveries.

Other IU researchers previously elected National Academy of Inventors fellows include Chandan Sen, PhD, of IU School of Medicine and David Clemmer, PhD; Richard DiMarchi, PhD; and Gary Hieftje, PhD–all of the Department of Chemistry in the College of Arts and Sciences at IU Bloomington.


IU School of Medicine is the largest medical school in the U.S. and is annually ranked among the top medical schools in the nation by U.S. News & World Report. The school offers high-quality medical education, access to leading medical research, and rich campus life in nine Indiana cities, including rural and urban locations consistently recognized for livability.